These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 32866563)
1. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. O'Cathail SM; Smith T; Owens R; Zeniou A; Tsang Y; Holyoake DLP; Murray L; Harrison M; Hawkins MA Radiother Oncol; 2020 Oct; 151():280-286. PubMed ID: 32866563 [TBL] [Abstract][Full Text] [Related]
2. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627 [TBL] [Abstract][Full Text] [Related]
3. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754 [TBL] [Abstract][Full Text] [Related]
6. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005 [TBL] [Abstract][Full Text] [Related]
7. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Sheikh S; Chen H; Sahgal A; Poon I; Erler D; Badellino S; Dagan R; Foote MC; Louie AV; Redmond KJ; Ricardi U; Biswas T Radiother Oncol; 2022 Feb; 167():187-194. PubMed ID: 34952002 [TBL] [Abstract][Full Text] [Related]
8. Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: a single center study. Gil-Raga M; Meri-Abad M; Safont Aguilera MJ; Hernández Machancoses A; Lobo M; Calabuig-Fariñas S; López Torrecilla J; Herreros Pomares A; Camps Herrero C Chin Clin Oncol; 2020 Apr; 9(2):13. PubMed ID: 32192350 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810 [TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer. Py JF; Salleron J; Courrech F; Beckendorf V; Croisé-Laurent V; Peiffert D; Vogin G; Dietmann AS Cancer Radiother; 2021 Jun; 25(4):350-357. PubMed ID: 33618909 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553 [TBL] [Abstract][Full Text] [Related]
13. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis. Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival. Qiu H; Katz AW; Chowdhry AK; Usuki KY; Singh DP; Metcalfe S; Cheruvu P; Chen Y; Okunieff P; Milano MT Am J Clin Oncol; 2018 Jan; 41(1):53-58. PubMed ID: 26270442 [TBL] [Abstract][Full Text] [Related]
15. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Badellino S; Levis M; Cuffini EM; Cerrato M; Orlandi E; Chiovatero I; Aprile A; Gastino A; Cavallin C; Iorio GC; Parise R; Mantovani C; Ricardi U Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326616 [TBL] [Abstract][Full Text] [Related]